Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of venetoclax + dexamethasone versus pomalidomide + dexamethasone in relapsed or refractory t(11;14)-positive multiple myeloma
CTR20200081Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax, pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Dec 2020; status: active.
02
Drugs
venetoclaxpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20200081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200081.